Table 1 |
|
|
Demographic and disease characteristics |
|
|
(n = 599) |
|
|
|
|
|
Agea (years) |
56.81 (10.84) |
|
Disease durationb (years) |
12 (20-6) |
|
Sex,a F (%) |
457 (76.29) |
|
CRP at baseline, median (IQR) mg/Lb |
34 (17-63) |
|
ESR at baseline, median (IQR) mg/Lb |
43 (27-68) |
|
DAS28 at baselinea |
6.36 (0.90) |
|
Change in DAS28a |
-2.01 (1.23) |
|
Concurrent DMARD n (%) |
449 (74.96) |
|
Infliximab |
272 (45.41) |
|
Etanercept |
220 (36.73) |
|
Adalimumab |
107 (17.86) |
|
|
|
|
CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; F, female; IQR, interquartile range; SD, standard deviation. aValues are expressed as mean (SD). bValues are expressed as median (IQR). All other values are n (%). Disease duration was measured in 598 patients; erythrocyte sedimentation rate (ESR) levels were measured in 578 patients; and change in DAS28 was measured in 442 patients. |
|
|
Plant et al. Arthritis Research & Therapy 2012 14:R214 doi:10.1186/ar4052 |
|
